BioLineRx names new board member
This article was originally published in Scrip
Jerusalem-based biopharmaceutical company BioLineRx, which is focused on in-licensing and developing therapeutic candidates, has named Dr Sandra Panem to its board of directors – effective from 24 February 2014. Dr Panem is currently a managing partner at Cross Atlantic Partners and is on the board of directors for Acorda Therapeutics, GenomeQuest, Labcyte, and MDx Medical.
You may also be interested in...
In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.
As the COVID-19 pandemic escalates, companies across the world are preparing to roll out commercial test kits for the detection of SARS-CoV-2.
Biopharmaceutical companies doubled-down on rare disease treatments during the last five years, thanks to a potent combination of scientific discovery and appealing business incentives.